Anixa Biosciences, Inc.
ANIX · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | — | — | -13.88M | -13.60M | -0.45 |
| 2023 FY | 210.00K | 49.00K | -11.01M | -9.81M | -0.32 |
| 2024 FY | — | — | -13.83M | -12.55M | -0.39 |
| 2025 FY | — | -36.00K | -11.70M | -10.93M | -0.34 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 30.41M | 2.21M | 12.36M | 221.00K | 29.05M |
| 2023 FY | 25.52M | 2.15M | 915.00K | 175.00K | 24.34M |
| 2024 FY | 21.59M | 2.70M | 1.27M | 232.00K | 20.00M |
| 2025 FY | 16.08M | 2.13M | 1.24M | 204.00K | 15.16M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | -6.49M | — | -6.49M | — | -16.77M |
| 2023 FY | -6.21M | — | -6.21M | — | -11.45M |
| 2024 FY | -7.34M | — | -7.34M | — | 356.00K |
| 2025 FY | -7.17M | — | -7.17M | — | -27.00K |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 170.09M | 157.96M | — | — | — |
| 2023 FY | 97.90M | 97.16M | — | — | — |
| 2024 FY | 111.64M | 110.60M | — | — | — |
| 2025 FY | 134.04M | 133.00M | — | — | — |
| 2026-10-31 | — | — | — | — | — |
| 2027-10-31 | — | — | — | — | — |
| 2028-10-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q3 | — | — | -2.44M | -2.26M | -0.07 |
| 2025 Q4 | — | -9.00K | -2.88M | -2.70M | -0.08 |
| 2026 Q1 | — | — | -2.72M | -2.57M | -0.08 |
| 2026 Q2 | — | — | -2.65M | -2.56M | -0.07 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q3 | 17.65M | 2.24M | 1.50M | 213.00K | 16.60M |
| 2025 Q4 | 16.08M | 2.13M | 1.24M | 204.00K | 15.16M |
| 2026 Q1 | 15.23M | 1.39M | 1.55M | 193.00K | 15.08M |
| 2026 Q2 | 14.87M | 1.64M | 1.48M | 184.00K | 14.48M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q3 | -1.51M | — | -1.51M | — | -415.00K |
| 2025 Q4 | -1.26M | — | -1.26M | — | -251.00K |
| 2026 Q1 | -2.61M | — | -2.61M | — | 303.00K |
| 2026 Q2 | -1.74M | — | -1.74M | — | -70.00K |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q3 | 99.38M | 98.09M | — | — | — |
| 2025 Q4 | 134.04M | 133.00M | — | — | — |
| 2026 Q1 | 101.05M | 99.70M | — | — | — |
| 2026 Q2 | 100.78M | 99.49M | — | — | — |
| 2026-07-31 | — | — | — | — | — |
| 2026-10-31 | — | — | — | — | — |
| 2027-01-31 | — | — | — | — | — |